MarginsXMarginsX
Home › Markets › Health Care › CLDI

Calidi Biotherapeutics Inc. (CLDI)

CLDI trades on NYSE in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.6023
-3.15% on the day
Market cap
$2.2M
Nano cap
Revenue · 2022
$45K
No prior year to compare
Net income · 2022
-$25.4M
-56504.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2022-12-31, https://www.sec.gov/Archives/edgar/data/1855485/000149315224010158/0001493152-24-010158-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2022-12-31.

Profile

FieldValue
TickerCLDI on NYSE
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryNot reported by the screener
IPO year2021
SEC CIK0001855485
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2022

LineValue
Revenue$45K
Net income-$25.4M
Operating income-$23.1M
Net margin-56504.4%
Operating margin-51395.6%
Revenue growthNo prior-year revenue to compare
Cash$590K
Total assets$2.6M
P/E (computed)Net income was not positive
P/S (computed)49.3×

Warning signs

Cash runway
2.9 months
$4.3M cash at June 30, 2026
Share count, 1 year
+669.9%
2025-11-10 to 2026-11-11 · +18588.2% over 3 years
Going-concern doubt
Yes
10-Q filed November 13, 2026
Insider net buying, 12 months
-$1K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"The Company estimates that based on the Company's liquidity resources, there is substantial doubt about the Company's ability to continue as a going concern within 12 months from the date of issuance of these unaudited condensed consolidated financial statements."
10-Q 2026-11-13
Cash and burn$4.3M cash; operating cash flow -$4.4M a quarter.Report 2026-06-30
Shares outstanding3,449,184 (2026-11-11); 7,167,721 a year earlier; 35,436,381 three years earlier. 1y figure adjusted for splits (1-for-16 overall); 3y figure adjusted for splits (1-for-1920 overall).Cover page 2026-11-11
Reverse splits, 3 years3; latest 1-for-16 on 2026-07-31Source 2026-07-31
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the marketLatest 2026-09-17
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-09-25
AuditorCBIZ CPAs P.C., Costa Mesa, California, United States; changed auditors 1 time in 24 months8-K 4.01 2025-05-02
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $1K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$4.2M-$4.4M$4.3M$600KNeeds four quarters10-Q 2026-08-13
Q1 2026
2026-03-31
Not filed-$4.1M-$4.1M$6.8M$600KNeeds four quarters10-Q 2026-05-14
Q4 2025
2025-12-31
Not filed-$4.1M-$5.0M$5.8M$600KNeeds four quarters10-K 2026-03-27
Q3 2025
2025-09-30
Not filed-$5.1M-$4.2M$10.6M$600KNeeds four quarters10-Q 2025-11-13
Q2 2025
2025-06-30
Not filed-$5.7M-$4.9M$5.4M$600KNeeds four quarters10-Q 2026-08-13
Q1 2025
2025-03-31
Not filed-$5.0M-$7.1M$10.8M$600KNeeds four quarters10-Q 2026-05-14
Q4 2024
2024-12-31
Not filed-$4.1M-$5.4M$9.6M$600KNeeds four quarters10-K 2026-03-27
Q3 2024
2024-09-30
Not filed-$5.1M-$4.9M$1.9M$2.4MNeeds four quarters10-Q 2025-11-13

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-09-17
Latest annual report10-K2026-03-27
Latest quarterly / interim10-Q2026-11-13
Latest current report8-K2026-11-13
Latest proxyDEFA14A2026-06-05

Source: SEC EDGAR submissions feed, 408 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-11.1%
1 month-30.9%
3 months-59.6%
Year to date-96.7%
1 year-97.4%
From 52-week high-97.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
VIVSVivoSim Labs Inc.$0.1237-2.68%$2.5M
CELZCreative Medical Technology Holdings Inc.$0.5201-1.51%$4.0M
LIMNLiminatus Pharma Inc.$2.97-0.67%$4.0M
CRISCuris Inc.$0.4358-2.07%$4.1M
BTTCBlack Titan Corporation$0.2873-9.20%$4.3M
SLXNSilexion Therapeutics Corp$1.76-11.11%$1.1M
SCNIScinai Immunotherapeutics Ltd.$0.4041+1.02%$1.1M
AIMAIM ImmunoTech Inc.$0.1310-8.77%$5.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier